ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Risperidone

Also written as “risperidone”, “Oral risperidone” and “Risperidone ISM 100 mg”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Psychotic Disorders · Autistic Disorder · Dementia, led by 15 companies.

Drug pageRisperidone: every studyMany companies study it; this page follows only the 99 they lead. All 262 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 4, 200399 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson670 open or runningphase 4since Jun 4, 2003May 2, 2002none ahead
Rovi Pharmaceuticals Laboratoriesits history only50 open or runningphase 3since May 12, 2017Feb 5, 2013none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 3since Apr 9, 2018Jan 26, 2009none ahead
AstraZenecaits history only30 open or runningphase 4since Nov 14, 2005May 2, 2002none ahead
Luye Pharma Groupits history only30 open or runningphase 1since Jan 31, 2014Jan 31, 2014none ahead
Lyndraits history only30 open or runningphase 3since Mar 9, 2023Sep 16, 2020none ahead
Braeburn Pharmaceuticalsits history only20 open or runningphase 3since May 11, 2016Jan 7, 2016none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Feb 4, 2010Feb 4, 2010none ahead
IPCA Laboratoriesits history only20 open or runningphase 1since Jun 11, 2012Jun 11, 2012none ahead
Sun Pharmaceutical Industriesits history only20 open or runningno phasesince Oct 15, 2010Oct 15, 2010none ahead

Also a collaborator on its studies: Otsuka and H. Lundbeck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jul 19, 2004.

  1. Jul 6, 2009Phase 4 study in SchizophreniaNCT00934635 · 2 enrolled · Germany
  2. Sep 25, 2009Phase 1 study in Bipolar DisorderNCT00986336 · 56 enrolled
  3. Oct 8, 2009Phase 4 study in SchizophreniaNCT00992407 · 75 enrolled · Korea, Republic of
  4. Jan 14, 2010Phase 4 study in SchizophreniaNCT01050582 · 244 enrolled · United States, Belgium, Germany and more
  5. May 25, 2012Phase 1 study in HealthyNCT01607762 · 31 enrolled · Belgium
  6. Jun 19, 2012Phase 3 study in Autistic DisorderNCT01624675 · 39 enrolled · Japan
  7. Nov 9, 2012Phase 4 study in SchizophreniaNCT01726335 · 53 enrolled · Brazil
  8. Mar 22, 2013Phase 4 study in SchizophreniaNCT01855074 · 80 enrolled
  9. Feb 17, 2014Phase 1 study in Psychotic DisordersNCT02087579 · 305 enrolled · United States, Argentina, Belgium and more
  10. Jun 2, 2015Phase 2 study in SchizophreniaNCT02462473 · 9 enrolled · United States
  11. Nov 2, 2015Phase 1 study in ImmunoassayNCT02634463 · 81 enrolled · Belgium
  12. Jul 14, 2017Phase 1 study in HealthyNCT03220867 · China
  13. Oct 18, 2018Phase 4 study in SchizophreniaNCT03713658 · 34 enrolled · Rwanda
  14. Jun 22, 2021Phase 4 study in SchizophreniaNCT04940039 · 93 enrolled · Rwanda

TargetBeta

“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
OlanzapineruleEli Lillyphase 476

Studies

The newest 60 of 67 Johnson & Johnson leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT04940039Schizophrenia · Rwanda4CompletedApr 16, 202493
NCT03713658Schizophrenia · Rwanda4CompletedDec 2, 201934
NCT03220867Healthy · China1WithdrawnJan 2, 20180
NCT02634463Immunoassay · Belgium1CompletedNov 9, 201681
NCT02462473Schizophrenia · United States2TerminatedJan 20169
NCT02087579Psychotic Disorders · United States, Argentina, Belgium and more1CompletedOct 2014305
NCT01855074Schizophrenia4CompletedFeb 200980
NCT01726335Schizophrenia · Brazil4CompletedMar 200853
NCT01624675Autistic Disorder · Japan3CompletedOct 201439
NCT01607762Healthy · Belgium1CompletedApr 201231
NCT01050582Schizophrenia · United States, Belgium, Germany and more4CompletedJul 2011244
NCT00992407Schizophrenia · Korea, Republic of4CompletedDec 201075
NCT00986336Bipolar Disorder1Completed56
NCT00934635Schizophrenia · Germany4TerminatedDec 20092
NCT00645502Schizophrenia1Completed40
NCT00576732Autistic Disorder · United States4CompletedSep 200996
NCT00558298Schizophrenia3Completed811
NCT00535132Schizophrenia · United States, Argentina, Colombia and more4CompletedJul 2008201
NCT00526877Schizophrenia · Taiwan4CompletedJan 31, 200931
NCT00495118Schizophrenia3Completed314
NCT00378183Psychotic Disorders4Completed120
NCT00378092Schizophrenia · South Africa4CompletedMar 201033
NCT00287742Alzheimer Disease3Terminated33
NCT00266552Conduct Disorder3Completed118
NCT00261508Autistic Disorder3Completed80
NCT00257075Bipolar Disorder3Completed267
NCT00254930Learning Disabilities3Completed19
NCT00253162Bipolar Disorder3Completed439
NCT00253149Bipolar Disorder3Completed158
NCT00253136Schizophrenia3Completed458
NCT00253123Dementia3Completed626
NCT00253110Schizophrenia4Completed396
NCT00250367Bipolar Disorder3Completed151
NCT00250354Conduct Disorder3Completed110
NCT00249236Bipolar Disorder3Completed291
NCT00249171Schizophrenia4Completed226
NCT00249158Dementia3Completed344
NCT00249145Dementia3Completed349
NCT00249132Schizophrenia3Completed523
NCT00249119Schizophrenia3Completed1,579
NCT00246285Schizophrenia3Completed381
NCT00246272Schizophrenia3Completed82
NCT00246246Bipolar Disorder3Completed48
NCT00240708Schizophrenia3Completed205
NCT00236587Schizophrenia3Completed100
NCT00236548Schizophrenia3Completed1
NCT00236470Attention Deficit and Disruptive Behavior Disorders3Completed232
NCT00236457Schizophrenia3Completed629
NCT00236444Attention Deficit and Disruptive Behavior Disorders3Completed375
NCT00236379Schizophrenia4Completed59
NCT00236353Schizophrenia3Completed86
NCT00216632Schizophrenia4CompletedJul 200799
NCT00216554Bipolar Disorder4Completed118
NCT00216528Schizophrenia4Completed527
NCT00210691Schizophrenia3Completed273
NCT00132678Bipolar Disorder · United States, Austria, India and more3CompletedOct 2007559
NCT00097032Bipolar Disorder3Completed30
NCT00095134Depressive Disorder, Major · United States3Completed630
NCT00094926Bipolar Disorder3Completed275
NCT00088075Schizophrenia3Completed160

How it is read

Names in the registry

  • “risperidone”, 40 entries
  • “Risperidone”, 34 entries
  • “Oral risperidone”, 5 entries
  • “Risperidone ISM 100 mg”, 3 entries
  • “LY03004”, 3 entries

Codes read as this program: LYN005.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.